<PAGE>
EXHIBIT 10.9
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN
PORTIONS OF THIS DOCUMENT. SUCH PORTIONS HAVE BEEN
REDACTED AND MARKED WITH ASTERISKS (**). THE NON-REDACTED
VERSION OF THIS DOCUMENT HAS BEEN SENT TO THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
AN APPLICATION FOR CONFIDENTIAL TREATMENT.
AMENDMENT NO. 1 TO
LICENSE AGREEMENT
Pursuant to Section 15.2 of the License Agreement dated as of April 15, 1999
between Pharmaceutical Applications Associates LLC, C. Donald Williams, M.D.,
C.G.P., Robert Murdock, R.Ph. and PRAECIS PHARMACEUTICALS INCORPORATED (the
"Agreement"), the parties hereto, intending to be legally bound, hereby agree as
follows:
Section 4.6 of the Agreement is hereby amended in its entirety to read as
follows:
4.6 In the event that Licensee elects, in its sole discretion,
to initiate a Phase III study of the Licensed Product, Licensee shall pay to PAA
the sum of *** dollars ($***) within sixty (60) days of the treatment of the
first patient.
Capitalized terms used herein and not otherwise defined shall have the meanings
ascribed to such terms in the Agreement.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
<PAGE>
IN WITNESS WHEREOF, the parties have duly executed this
Amendment No. 1 to the Agreement as of this 25th day of August, 2000.
PRAECIS PHARMACEUTICALS INCORPORATED
/s/ Marc A. Silver
------------------------------------------
Marc A. Silver
Vice President of Corporate Development
PHARMACEUTICAL APPLICATIONS ASSOCIATES LLC
By /s/ C. Donald Williams, M.D., C.G.P.
------------------------------------------
Name: C. Donald Williams, M.D., C.G.P.
Title: President
